Searched for
LUPIN HEALTHCARE
Capitalmind Flexi Cap Fund adds Nestle India and 10 others, exits SBI and 14 others in MayCapitalmind Flexi Cap Fund made significant portfolio adjustments in May. The fund welcomed Nestle India and eleven new stocks. It also div...- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- 6 pharma stocks that Bernstein sees up to 40% upside potential. Do you own any?Bernstein initiated coverage on six pharma stocks, expressing a positive outlook on the Indian healthcare sector driven by AI, innovation i...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Bank Nifty near key resistance zone; breakout above 54,300 crucial: Ajit MishraIndian equity markets are consolidating within a narrow range, with Nifty struggling to break 24,000 and Bank Nifty showing relative streng...
- Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- Bain Capital sole contender for Vitabiotics buyBain Capital has emerged as the frontrunner to acquire Vitabiotics, as rival bidders TPG Capital and EQT exit the process, potentially lowe...
- Lupin acquires UK-based firm for 12.3 million poundsLupin has acquired UK-based Renascience Pharma for £12.3 million, enhancing its branded medicine portfolio. The acquisition allows Lupin to...
- Lupin's arm gets UK regulator nod for COPD treatmentGlobal pharma major Lupin Limited on Friday announced that its UK subsidiary, Lupin Healthcare (UK) Limited, has received approval from the...
- Lupin inks pact with Shenzhen Foncoo to introduce products in ChinaThe company would continue to explore additional partnership opportunities in China to leverage its global portfolio including complex gene...
- Lupin forays into diagnostics, to open 100 labs pan India in next 3 yearsThe company launched operations with 11 labs including a 45,000 square feet national reference lab in Navi Mumbai and 200 collection centre...
- Lupin announces launch of its diagnostics businessCommenting on the development, Lupin Managing Director Nilesh Gupta said, "combining decades of experience and knowledge in the field of th...
- Lupin to enter digital healthcare space in IndiaDrug major Lupin on Thursday said it will enter the digital healthcare space in India with a focus to provide a digital therapeutics platfo...
- LupinLife partners with Uttarakhand Police to promote hand hygiene at Kumbh MelaDrug firm Lupin on Wednesday said its consumer healthcare business LupinLife has partnered with the Uttarakhand Police to promote hand hygi...
- Lupin, Cadila recall drugs in US MarketZydus Pharmaceuticals USA Inc, arm of Cadila Healthcare, is also recalling 19,812 bottles of Paroxetine tablets in the strength of 30 mg fr...
- Lupin launches HIV drug in the US with marketing exclusivityLupin launched the generic version of ViiV Healthcare's Trizivir tablets in the US market with 180-days of marketing exclusivity.
- Lupin is a buy: Vikas Khemani, Edelweiss Securities LtdPharma space is a very good space and there is a reasonably good amount of growth visibility.
Load More
